Novo Nordisk to Expand Access to Wegovy with WeightWatchers Partnership
Novo Nordisk NOVO.B -0.99%decrease; red down pointing triangle plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.
The pharmaceutical giant said Thursday WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions. WeightWatchers aims to streamline the patient experience with convenient access to medication approved by the Food and Drug Administration as well as lifestyle support, Novo Nordisk said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
13 minutes ago
- Time Magazine
TIME100 Most Influential Companies 2025: Vertex Pharmaceuticals
Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S. FDA, called Casgevy, which treats sickle-cell disease and beta thalassemia; received approval for its fifth cystic fibrosis treatment, and in January, also earned FDA approval for the first non-opioid pain killer, Journavx, in more than two decades. CEO Dr. Reshma Kewalramani is a triple threat, combining medical, research, and business experience to lead the 36-year-old company. She has continued the drug development pathway on which the company was founded: rational drug design, meaning designing drugs to address a known biological process, rather than spending time with the traditional trial and error practice of combining and testing chemicals in the hope of landing on one that has the desired effect. When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani leans on a specific formula: Vertex concentrates on diseases where there aren't many treatment options, or high unmet need; they look for genetic or drug targets that animal models show can make a difference in the disease; the disease needs to have so-called biomarkers, or ways that researchers can track changes produced by the treatment; and the therapy developed should have a clear pathway for getting approval from regulatory agencies like the FDA. The approach has served the company well. Its market capitalization is around $114 billion, and total revenues were up 12% from the previous year. Treating pain in a way that avoided the addictive side effect of opioids checked all of these boxes, although it took two decades to identify the right pathway to target. 'Why did we do this? Because we thought pain was an incredibly important disease where there was no innovation and where we thought we could make a big difference,' says Kewalramani. 'And why did we keep going? Because of the science and our desire to work in areas where we could make this kind of transformative leap.' Following the launch of Casgevy, which allows people with sickle cell disease to receive a single CRISPR gene therapy to address the genetic mutation responsible for their disease, Vertex is continuing to pursue what Kewalramani calls 'one and done curative medicines.' They are in the late stages of testing a cell-based treatment for type 1 diabetes that could potentially help people skip regular insulin injections by giving them healthy insulin-making pancreatic beta cells. The company is also developing new treatments for chronic kidney disease, for which there have not been new options in almost a decade, and in 2024, Vertex bought Alpine Immune Sciences for $4.9 billion to accelerate its search for novel kidney treatments. 'We are simply not interested in making me-too medicines,' says Kewalramani.
Time Magazine
17 minutes ago
- Time Magazine
TIME100 Most Influential Companies 2025: Gilead
It's been more than four decades since the first cases of HIV emerged, and while there are effective drug treatments to control the virus, there's still no vaccine. But it turns out that an anti-HIV drug, injected twice a year, could be just as effective as a vaccine in protecting people from getting infected, according to strong results from studies published in 2024. Leading HIV treatment developer Gilead's scientists spent 20 years developing lenacapavir, an antiviral drug that targets a specific protein on the virus' shell. Vaccines have similarly targeted other outer viral proteins, and the idea is that priming the immune system to recognize this part of HIV can help it to generate defenses against the virus if someone is later exposed. Lenacapavir was already approved to treat HIV, and in June the FDA also approved it as a preventive therapy. Widespread use of the medication could bring the world closer to ending the HIV epidemic. The company's CEO Dan O'Day says Gilead is equally committed to ensuring that those who are at highest risk of getting infected with HIV have access to the drug. He signed a voluntary licensing agreement in 2024 that allows half a dozen generic manufacturers to make lenacapavir for 120 low and middle income countries, where HIV remains a significant threat. Close to 40 million people have HIV or AIDS globally, but a disproportionate number—about two-thirds—live in subsaharan Africa. 'Not that many companies focus on virology,' he says. 'And if we are going to produce a drug, and put our blood, sweat and tears into it, then it's got to end up in everybody's hands who can use it.' Expanding on its expertise in immune-based treatments—the company's remdesivir was the first antiviral approved to treat COVID-19—O'Day says Gilead is also developing treatments for blood and solid cancers as well as autoimmune diseases. 'We are in build mode, but it is already a significant part of our company and the fastest-growing part of the company today,' he says of the cancer projects. 'I expect five years from now you will see Gilead making a bigger impact across the world, in a variety of disease states.'
Yahoo
an hour ago
- Yahoo
Kennedy's vaccine panel votes to remove preservative long targeted by activists
ATLANTA — A panel of vaccine advisers selected by Health Secretary Robert F. Kennedy Jr. voted Thursday to recommend that no one get a flu vaccine that contains thimerosal — a preservative that has long been a target of the anti-vaccine movement and Kennedy himself. Five members voted to recommend that no children, pregnant women, or adults get any flu vaccine with thimerosal. If the CDC adopts the recommendation, it will mark one of the first major changes in federal vaccine guidance and access as Kennedy embarks on his goal of remaking immunization policy in his image. 'The risk from influenza is so much greater than the nonexistent, as far as we know, risk from thimerosal,' said Dr. Cody Meissner, the only panel member who voted no. 'I would hate for a person not to receive the influenza vaccine because the only available preparation is with thimerosal." The CDC director usually needs to endorse the recommendations before they are official. But Kennedy will likely be the one to endorse these recommendations because there is currently no CDC director or acting director. The decision came after a presentation from Lyn Redwood, a former president of the Kennedy-founded anti-vaccine group Children's Health Defense, who identified herself as a 'private citizen.' The Washington Post reported Wednesday that Kennedy had hired Redwood to work in the CDC's vaccine safety office. The HHS directory lists Redwood as an 'expert' in the Office of the Assistant Secretary for Health. Department spokespeople and Redwood didn't respond to requests for comment on Redwood's role. Redwood's presentation largely argued that thimerosal, a preservative that has been used in vaccines since the 1930s, should be removed from the products because of safety concerns. The CDC website says that there is 'no evidence of harm caused by the low doses of thimerosal in vaccines, except for minor reactions like redness and swelling at the injection site.' A CDC background document for members of the Advisory Committee on Immunization Practices, posted by the agency on Tuesday and later removed from its website, also diverges from Redwood's conclusion, arguing there is overwhelming evidence that thimerosal-containing vaccines do not cause neurological problems. ACIP member Dr. Robert Malone said the document was removed because 'it was not authorized by the office of the secretary.' Redwood's presentation argued there is evidence that thimerosal can cause serious complications, especially for pregnant women. 'The fact that thimerosal from vaccines has been documented to raise blood mercury levels over known thresholds where developmental effects have been documented to occur during the first few months of life, means that particular 'windows of vulnerability' may have been breached,' Redwood said. Thimerosal continues to be used as a preservative in multi-dose vaccine vials to inhibit germ growth, but the vast majority of FDA-licensed flu vaccines are already thimerosal-free — 96 percent of all flu vaccines in the U.S. last season didn't contain the preservative, according to the CDC document removed from the website. It was largely removed from childhood vaccines in 2001, and several pediatric products — including the measles, mumps and rubella and varicella shots — never included the ingredient. In 1999, the FDA and CDC announced plans to work with manufacturers to reduce or remove thimerosal from vaccines. But the move was a precautionary measure, and further research has identified no link between the ingredient and neurological defects. Several ACIP members agreed with Redwood, including committee Chair Martin Kulldorff, who argued that while the level of thimerosal in vaccines may be safe, it could contribute to high cumulative mercury exposure. But Meissner, a pediatrics professor at Dartmouth College's medical school, pushed back strongly against Redwood's assertion. 'I'm not quite sure how to respond to this presentation,' Meissner said. He went on to note that thimerosal is metabolized into ethylmercury and thiosalicylate, not methylmercury, which is found in fish and shellfish and is highly toxic to humans. 'Ethylmercury is excreted much more quickly from the body, and is not associated with the high neurotoxicity that methylmercury has,' Meissner noted. 'Of all the issues that I think ACIP needs to focus on, this is not a big issue,' he added. Many public health experts on the call also pushed back. Jason Goldman of the American College of Physicians asked whether the committee would get an 'actual CDC presentation done by staff, scientists, physicians and those who are subject matter experts with accurate, peer-reviewed scientific data or the ability for the committee to review [the data]' or if they would just hear 'layperson presentations.' Separately, the panel also recommended the updated influenza vaccine for the upcoming fall and winter season. Six members voted to approve, while Vicky Pebsworth, a public health scientist and nurse who's served on the board of an anti-vaccine group, abstained. Members of the press were not allowed to leave the press area, largely preventing them from speaking with the members of the committee. Kulldorff declined to answer questions following the meeting. 'This committee strongly supports the use of vaccines and other counter measures predicated on evidence-based medicine, including rigorous evaluation and expansive credible scientific data for both safety and efficacy,' the committee said in a statement after the meeting concluded. 'All stakeholders, including healthcare providers, parents, children, schools, nursing homes, insurance providers, public health agencies, manufacturers and the rare few who may be harmed by recommended interventions need to have understandable, digestible, scientifically correct information.' The CDC's vaccine advisory committee may consider at its next meeting a proposal to advise against giving a combination shot against measles and chickenpox to children under 4, Kulldorff said Thursday after delivering a presentation on the product. Under the current childhood immunization schedule, the CDC recommends that children receive two doses of the measles, mumps and rubella vaccine and the varicella vaccine — the first between 12 and 15 months and the second between 4 and 6 years of age. An MMR-chickenpox combination vaccine, known as MMRV, may be used, but the agency advises that the first dose be administered as two separate shots. ACIP updated its recommendation in 2009 to recommend separate MMR and varicella vaccinations for younger children due to an increased risk of febrile seizures in children under 2 who received the combination shot compared with those who got the two distinct vaccines. Fever-induced seizures are common in young children — the CDC estimates the risk at 5 percent — but don't cause permanent harm. 'A proposed recommendation — we're not going to vote on that this time, but possibly at the next meeting — could be that, as there exists a safer, equally effective alternative, the MMRV vaccine should not be administered to children under the age of 47 months,' Kulldorff said.
